Streetbeat News

Products Services

WIX

Wix is expected to report its Q3 earnings, with potential benefits from AI product offerings and WIX Studio.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

ALL

Allstate has announced partnerships with Thatch, Intuit QuickBooks, and Ambetter Health to offer flexible healthcare solutions to its customers.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

BKR

The article discusses the potential benefits for the energy sector during Donald Trump's presidency, highlighting policies that encourage increased oil production and potentially lower gas prices.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

MYGN

Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. (MYGN) for potential violations of federal securities laws. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 1, 2025.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

HYPRF

HydrogenPro has successfully met the new regulations set by the European Hydrogen Bank, which limit the sourcing of electrolyser stacks from China to 25%. This compliance positions HydrogenPro favorably in the European market.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

SONO

Sonos has launched the Era 100 Pro, a new solution aimed at transforming professional audio installations in both light-commercial and residential settings.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

LQDA

UTHR

Liquidia Corporation's Yutrepia, a competitor to United Therapeutics' Tyvaso, is expected to enter the market in 2025. Despite financial challenges and competition, Liquidia's low valuation and upcoming product launches make it an attractive investment. Legal battles with United Therapeutics are nearing resolution, potentially allowing Yutrepia's commercial launch by mid-2025.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

NGNE

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential violations of federal securities laws. This follows a press release by Neurogene reporting interim clinical data from a Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

BIIB

The CHMP has given a positive opinion recommending the approval of Biogen and Eisai's Leqembi for treating early Alzheimer's disease in Europe.

Portfolio Pulse from

November 15, 2024 | 3:15 pm

RMD

ResMed's strong sales in masks and devices are positive for the company, but its increasing debt burden is a concern for investors.

Portfolio Pulse from

November 15, 2024 | 3:15 pm